141282-26-0

Basic information

• Product Name: 1H-Isoindole-1,3(2H)-dione, 2-[2-[2-[[(4-methylphenyl)sulfonyl]oxy]ethoxy]ethyl]-
• CAS NO: 141282-26-0
• Molecular Formula: C19H19NO6S
• Molecular Weight: 389.429
• Mol File: 141282-26-0.mol

Chemical Properties

• CAS DataBase Reference: 1H-Isoindole-1,3(2H)-dione, 2-[2-[2-[[(4-methylphenyl)sulfonyl]oxy]ethoxy]ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Isoindole-1,3(2H)-dione, 2-[2-[2-[[(4-methylphenyl)sulfonyl]oxy]ethoxy]ethyl]-(141282-26-0)
• EPA Substance Registry System: 1H-Isoindole-1,3(2H)-dione, 2-[2-[2-[[(4-methylphenyl)sulfonyl]oxy]ethoxy]ethyl]-(141282-26-0)

Safety Data

• Hazardous Substances Data: 141282-26-0(Hazardous Substances Data)

Upstream product

• 69676-63-7 2-(2-phthalimidoethoxy)ethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 85-44-9 phthalic anhydride 
• 136918-14-4 phthalimide 
• 7460-82-4 diethylene glycol ditosylate 

Downstream Products

• 880098-49-7 1-{2-[2-(2-phthalimidoethoxy)ethoxy]ethyl}-3-benzyloxypyridine-2(1H)-one 
• 1219133-24-0 C₄₅H₄₇NO₄ 
• 1618136-53-0 C₃₀H₂₆N₃O₅⁽¹⁺⁾*C₇H₇O₃S^(1-) 

Relevant articles and documents

Cooperative and receptor for ion-pairs

A novel heteroditopic calix[4]diquinone receptor capable of binding an anion and cation simultaneously in a cooperative fashion is shown only to recognise halide anions in the presence of a suitable cobound cationic guest species, and displays affinity for certain ion-pairs where no affinity for either of the free ions is observed. The Royal Society of Chemistry 2006.

IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein NA (I) and pharmaceutically acceptable salts thereof.5 Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS

The invention provides novel imidazopyrazine derivatives having general formula (I), wherein R1 to R11 are as described herein, and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R14 are as described herein (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein formula (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

NOVEL IMIDAZOPYRAZINE DERIVATIVES

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

Synthesis and in vitro antitumor activity of novel 2-alkyl-5- methoxycarbonyl-11-methyl-6H-pyrido[4,3-b]carbazol-2-ium and 2-alkylellipticin-2-ium chloride derivatives

Twenty-one types of novel ellipticine derivatives and pyridocarbazoles (5-methoxycarbonyl-11-methyl-6H-pyrido[4,3-b]carbazoles) with a nitrosourea moiety, linked by an oxydiethylene unit at the 2 position, were synthesized, and their cytotoxicity against HeLa S-3 cells was evaluated. Some of these new compounds exhibited potent antitumor activity by comparison with that of ellipticine.

Design and synthesis of protoporphyrin IX/vitamin B12 molecular hybrids via CuAAC reaction

The design and synthesis of new molecular hybrids composed of protoporphyrin IX (PPIX) and vitamin B12 via copper catalyzed alkyne azide cycloaddition reaction is described. New, clickable aminoazide and aminoalkyne linkers were prepared and subsequently attached to PPIX (via vinyl group) and to vitamin B12 giving desired building blocks. Preliminary results showed that respective water soluble hybrids were formed under CuAAC reaction. Gratifyingly, Cu incorporation into the PPIX core was avoided, which was important for further biological studies. Copyright

Tuning the strength and selectivity of ion-pair recognition using heteroditopic calix[4]arene-based receptors

The syntheses, characterisation and ion binding properties of two novel heteroditopic calix[4]arene receptors are reported. These systems were found to demonstrate cooperative binding of certain ion-pairs, with the selectivity depending critically on the structure of the receptors. Furthermore, a macrocyclic effect for ion-pair recognition was observed to operate. The Royal Society of Chemistry and the Centre National de la Recherche Scientifique.

Allosteric binding of alkali metal ions to a pseudocryptand formed by a C-pivot tripodal ligand containing 3-hydroxy-2(1H)-pyridinone and Ga(III)

A novel C-pivot tripodal hexadentate ligand (3,2-HOPOHL) composed of 3-hydroxy-2(1H)-pyridinone as a bidentate ligand, the ethyleneoxy chain as a spacer, and tris(carboxyric acid) as an anchor was synthesized. 3,2-HOPOHL recognized only Na+ ion, suggesting that it pre-organized a cavity due to the electrostatic interaction among the 2(1H)-pyridinone rings. UV-VIS spectroscopic analysis indicated that 3,2-HOPOHL formed a stable intramolecular 1:1 Fe(III) complex in aqueous solution. The stability constant (log K) of 3,2-HOPOHL-Fe(III) complex was estimated to be 27.6 from the competitive reaction with EDTA. 1H-NMR titration of 3,2-HOPOHL-Ga(III) complex with Na+ and K+ ions in CDCl3-CD3CN indicated the formation of 1:1 complexes. The binding constants of Na+- and K+-3,2-HOPOHL-Ga(III) complexes were estimated to be 3.3×103 and 7.8×103 M-1, respectively, the ion selectivity of K+ toward Na+ being more than two-fold.